In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has approved the first needle-free alternative to EpiPens for the treatment of severe allergic reactions, known as anaphylaxis. This new treatment, called Neffy, is a nasal spray formulation of epinephrine, the same life-saving medication found in EpiPens. Key Factor Details Approval First needle-free epinephrine…
In a significant move, the U.S. Food and Drug Administration (FDA) has announced the full availability of all doses of Eli Lilly’s weight-loss and diabetes drug, Zepbound, after a period of shortages. This injectable medication, which contains the active ingredient tirzepatide, is designed to aid weight management and treat type 2 diabetes. What is Zepbound?…
In a significant move to improve early detection of colorectal cancer, the FDA has approved several new blood-based screening tests. These innovative tests, such as Guardant Health’s Shield and Exact Sciences’ Cologuard, aim to make colon cancer screening more accessible and less invasive, potentially increasing screening rates and saving lives. Understanding Colorectal Cancer Screening Colorectal…
The FDA has approved a new blood test called Shield, developed by Guardant Health, Inc., for the early detection of colorectal cancer. This innovative test is designed to identify colorectal cancer-related alterations in cell-free DNA (cfDNA) from a blood sample, offering a less invasive alternative to traditional diagnostic methods. What is Shield? Shield is a…
The U.S. Food and Drug Administration (FDA) has recently approved the Guardant360 CDx, a groundbreaking liquid biopsy test developed by Guardant Health, Inc. This innovative test combines liquid biopsy and next-generation sequencing (NGS) technologies to detect genetic mutations in circulating cell-free DNA (cfDNA) from blood samples, aiding in the diagnosis and treatment of various cancers,…
